Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations

Apr 02 2020

• By Eileen Francis

Magnifying glass-FDA_418713547_1200.jpg

Related Content

DeLauro, Durbin Reheat Proposal For Separate Food Safety Agency

Feb 02 2015

Heparin Fallout Likely To Impact Supplement Ingredient Testing Exemptions

Apr 07 2008

Ranitidine’s US Future In Limbo As Tests Continue; ‘Glow-Boosting’ Mask Also Among Recent Recalls

Mar 09 2020

DeLauro Renews Push To Give FDA Mandatory Recall Authority For Drugs

Jan 12 2020

Australia Suspends 23 Ranitdine Products Contaminated with NDMA

Nov 28 2019

Online Pharmacy Stirs Ranitidine Controversy With Petition To Halt Sales

Sep 15 2019

Related Companies

Sanofi

Additional Topics

United States OTC Drugs FDA Recalls Commercial Companies Compliance Drug Approval Standards Generic Drugs Ingredients Legislation Manufacturing Policy Regulation Safety Consumer Gastrointestinal

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window